Page last updated: 2024-09-05

erlotinib hydrochloride and camptothecin

erlotinib hydrochloride has been researched along with camptothecin in 40 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (camptothecin)	Trials (camptothecin)	Recent Studies (post-2010) (camptothecin)
4,353	786	3,033	13,002	2,229	5,391

Protein Interaction Comparison

Protein	Taxonomy	camptothecin (IC50)
Histone deacetylase 3	Homo sapiens (human)	0.05
Multidrug resistance-associated protein 4	Homo sapiens (human)	7.4
DNA topoisomerase 1	Homo sapiens (human)	1.9799
Somatostatin receptor type 1	Homo sapiens (human)	0.0022
Somatostatin receptor type 2	Homo sapiens (human)	0.0022
Somatostatin receptor type 4	Homo sapiens (human)	0.0022
Somatostatin receptor type 3	Homo sapiens (human)	0.0022
Somatostatin receptor type 5	Homo sapiens (human)	0.0022
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	0.97
Histone deacetylase 4	Homo sapiens (human)	0.05
Histone deacetylase 1	Homo sapiens (human)	0.05
Histone deacetylase 7	Homo sapiens (human)	0.05
Histone deacetylase 2	Homo sapiens (human)	0.05
Polyamine deacetylase HDAC10	Homo sapiens (human)	0.05
Histone deacetylase 11	Homo sapiens (human)	0.05
Histone deacetylase 8	Homo sapiens (human)	0.05
Histone deacetylase 6	Homo sapiens (human)	0.05
Histone deacetylase 9	Homo sapiens (human)	0.05
Histone deacetylase 5	Homo sapiens (human)	0.05

Research

Studies (40)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (30.00)	29.6817
2010's	26 (65.00)	24.3611
2020's	2 (5.00)	2.80

Authors

Authors	Studies
Albanell, J; Baselga, J	1
Maneely, D	1
Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN	1
Masuda, N; Yanase, N; Yokoba, M	1
Ko, AH; Tempero, MA	1
Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H	1
Adames, V; Chen, J; Fritzky, L; Higgins, B; Kolinsky, K; Linn, M; Mehta, N; Rashed, M; Smith, M; Wheeldon, E	1
Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG	1
Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P	1
Davies, JM; Goldberg, RM	1
Hasmann, M; Klein-Scory, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schoeneck, A; Schulmann, K; Schwarte-Waldhoff, I; Stricker, I; Tannapfel, A	1
Li, J; Saif, MW	1
Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK	1
Mehta, SP	1
Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y	1
House, L; Liu, Y; Ramírez, J; Ratain, MJ	1
Adjei, AA; Garmey, E; Schwartz, B	1
Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T	1
Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H	1
Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M	1
Kim, R; Kothari, N; Saif, MW	1
Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB	1
Bobilev, D; Peleg, R; Priel, E	1
Chan, EH; Chan, SL; Chan, ST; He, ZX	1
Yano, S	1
Aichler, M; Buck, A; Eickelberg, O; Fernandez, IE; Hauck, SM; Huber, K; Janssen, KP; Keller, U; Li, Z; Sun, N; Walch, A; Zitzelsberger, H	1
Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N	1
Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY	1
Fadlalla, K; Gales, DN; Manne, U; Putcha, BD; Samuel, T	1
Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR	1
Baroian, N; Buchner, P; Czejka, M; Dittrich, C; Sahmanovic, A; Schreiber, V	1
Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M	1
Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K	1
Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM	1
Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A	1
An, HJ; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, Y; Lim, KY; Moon, SH; Nam, BH; Yun, T	1
Gao, L; Li, J; Niu, B; Wu, X; Ye, R; Zhao, Z	1
Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM	1
Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R	1
Al-Jumayli, M; Miller, K; Park, R; Saeed, A	1

Reviews

13 review(s) available for erlotinib hydrochloride and camptothecin

Article	Year
Epithelial growth factor receptor interacting agents. Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays	2002
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine	2005
Systemic therapy for pancreatic cancer. Seminars in radiation oncology, 2005, Volume: 15, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines	2005
[Chemotherapy for lung cancer patients]. Journal of UOEH, 2006, Mar-01, Volume: 28, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids	2006
Targeted therapy in rectal cancer. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A	2007
First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park, N.Y.), 2008, Nov-30, Volume: 22, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex	2008
Palliative chemotherapy for pancreatic malignancies. The Surgical clinics of North America, 2010, Volume: 90, Issue:2 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus	2010
First-line treatment for advanced pancreatic cancer. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic	2013
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chinese journal of cancer, 2014, Volume: 33, Issue:6 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor	2014
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma	2014
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids	2014
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. Clinical colorectal cancer, 2016, Volume: 15, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Quality of Life	2016
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment	2020

Trials

6 trial(s) available for erlotinib hydrochloride and camptothecin

Article	Year
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19 Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome	2004
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines	2009
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status. Cancer research and treatment, 2017, Volume: 49, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome	2017
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer. Medicine, 2017, Volume: 96, Issue:30 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome	2017
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer. Anticancer research, 2019, Volume: 39, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds	2019

Other Studies

21 other study(ies) available for erlotinib hydrochloride and camptothecin

Article	Year
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK. IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome	2003
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Transplantation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous	2007
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dimerization; Drug Therapy, Combination; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2009
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP : Journal of the pancreas, 2009, Jul-06, Volume: 10, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome	2009
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. Annals of surgical oncology, 2010, Volume: 17, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured	2010
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Molecular cancer therapeutics, 2010, Volume: 9, Issue:7 Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays	2010
The UGT1A128 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11* Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Drug Combinations; Erlotinib Hydrochloride; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Phenotype; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Young Adult	2010
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. The oncologist, 2011, Volume: 16, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor	2011
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome	2011
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer research, 2012, Feb-01, Volume: 72, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays	2012
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncology reports, 2012, Volume: 27, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays	2012
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin. International journal of oncology, 2014, Volume: 44, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines	2014
A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies. Histochemistry and cell biology, 2014, Volume: 142, Issue:4 Topics: Administration, Intravenous; Administration, Oral; Afatinib; Animals; Camptothecin; Erlotinib Hydrochloride; In Vitro Techniques; Irinotecan; Liver; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Animal; Molecular Structure; Pyridones; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2014
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Pancreas, 2014, Volume: 43, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome	2014
Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC cancer, 2014, Aug-18, Volume: 14 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Erlotinib Hydrochloride; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Phleomycins; Quinazolines; Signal Transduction	2014
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scandinavian journal of gastroenterology, 2014, Volume: 49, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome	2014
A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies. Pharmacology, 2015, Volume: 95, Issue:1-2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carboxylesterase; Cytidine Deaminase; Deoxycytidine; Enzyme Activation; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines	2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2016
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases. The American Journal of dermatopathology, 2017, Volume: 39, Issue:10 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male	2017
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Digestion, 2016, Volume: 94, Issue:4 Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires	2016
Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer treatment and research communications, 2021, Volume: 27 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mutation; Neoplasm Staging; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Treatment Outcome	2021